AgeX Therapeutics Inc
AGE
Get informed when a big investor buys or sells
+ FollowMarket Cap$181.87M
Close$
$-3.97
135.8% downside
Current Fair Value
135.8% downsideOvervalued by 135.8% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $181.87 Million |
|---|---|
| Enterprise Value | $158.97 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-1.91 |
| Beta | 1.19 |
| Outstanding Shares | 16,385,000 |
Return
| Return on Equity | -128.36% |
|---|---|
| Return on Assets | -93.14% |
| Return on Invested Capital | -87.97% |
Valuation & Multiples
| P/E Ratio | -0.88 |
|---|---|
| PEG | -2.28 |
| Price to Sales | - |
| Price to Book Ratio | 11.1 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -8.19 |
| Enterprise Value to Net Income | -7 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0.01 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
March 25, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About AgeX Therapeutics Inc
CEO: Michael West